Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

→ Un­der fire for its pric­ing pol­i­cy on its HIV pre­ven­tion pill Tru­va­da, Gilead $GILD has agreed to al­low one gener­ic drug­mak­er Te­va $TE­VA to be­gin sell­ing a copy­cat ver­sion of the drug by Sep­tem­ber 30, 2020 — about one year ahead of three oth­er com­pa­nies who have at­tempt­ed to launch their own ver­sions (Am­neal, Au­robindo and My­lan), the US drug­mak­er in­di­cat­ed in a fil­ing post­ed on Wednes­day. A coali­tion of AIDS ac­tivists — in­clud­ing ACT UP New York, Health GAP, Hous­ing Works, #PrEP4All Col­lab­o­ra­tion — al­so dis­rupt­ed Gilead’s an­nu­al gen­er­al meet­ing of share­hold­ers on Wednes­day, con­fronting new­ly crowned chief Daniel O’Day with de­mands that Gilead stop ob­struct­ing ac­cess to Tru­va­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER